Cargando…
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
OBJECTIVES: The aim of this study was to understand how demographic and treatment-related factors impact responses to fostemsavir-based regimens. DESIGN: BRIGHTE is an ongoing phase 3 study evaluating twice-daily fostemsavir 600 mg and optimized background therapy (OBT) in heavily treatment-experien...
Autores principales: | Ackerman, Peter, Thompson, Melanie, Molina, Jean-Michel, Aberg, Judith, Cassetti, Isabel, Kozal, Michael, Castagna, Antonella, Martins, Marcelo, Ramgopal, Moti, Sprinz, Eduardo, Treviño-Pérez, Sandra, Streinu-Cercel, Adrian, Latiff, Gulam H., Pialoux, Gilles, Kumar, Princy N., Wang, Marcia, Chabria, Shiven, Pierce, Amy, Llamoso, Cyril, Lataillade, Max |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183480/ https://www.ncbi.nlm.nih.gov/pubmed/33946085 http://dx.doi.org/10.1097/QAD.0000000000002851 |
Ejemplares similares
-
365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
por: Dyson, Alftan, et al.
Publicado: (2023) -
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
por: Aberg, Judith A., et al.
Publicado: (2023) -
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
por: Gartland, Margaret, et al.
Publicado: (2022) -
Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
por: Anderson, Sarah-Jane, et al.
Publicado: (2021) -
834. Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial
por: Chabria, Shiven, et al.
Publicado: (2021)